Amgen's request for full approval of Lumakras in lung cancer denied by FDA
Fierce Pharma
DECEMBER 27, 2023
Amgen’s request to gain full approval of Lumakras in non-small cell lung cancer has been rejected by the FDA. | Amgen’s request to gain full approval of Lumakras in non-small cell lung cancer has been rejected by the FDA. The California biopharma will now have to conduct an additional confirmatory trial to gain the coveted FDA nod.
Let's personalize your content